Table 1.
Patient demographics and pre-operative characteristics
| Case. age at last follow-up,years/Sex | Eye, R/L | LSCD, unilateral/bilateral | Days in culture | LSCD, partial/total | Aetiology of LSCD | Previous procedures | Post-operative topical therapy | Post-operative immunosuppressive or systemic ocular therapy or both |
|---|---|---|---|---|---|---|---|---|
| 1. 40/M | R | B | 14 | T | Aniridia | Limbal tissue allograft + SK*, CE/IOL | FML, cellufresh tears, timolol | Minocycline 50 mg, mycophenolate mofetil 500 mg BD |
| 2. 77/F | R | U | 10 | T | Primary acquired melanosis; multiple surgeries/topical mitomycin C therapy | Multiple conjunctival excisions | Predsol minims | Nil |
| 3. 73/F | R | U | 10 | T | Recurrent melanoma; multiple surgeries | Multiple conjunctival excisions, cryotherapy, lid repair, HAM transplant | Cellufresh tears, dexa minims | Nil |
| 4. 68/M | L | B | 11 | P | Query trachoma-induced | Ptosis repair | Cellufresh tears, dexa minims | Nil |
| 5. 61/M | R | U | 9 | T | Chemical burn | Limbal tissue allograft* | Dexa minims | Doxcycline 100 mg |
| 6. 65/F | R | B | 16 | T | Aniridia | 2xPK*, cyclodiode laser | Dexa minims, timolol | Nil |
| 7. 33/M | L | U | 14 | T | Chemical burn | HAM transplant + nexagon application* | Dexa minims | Nil |
| 8. 50/M | L | U | 14 | T | Chemical burn | Ptosis repair, PK*, limbal tissue allograft + PK*, CE/IOL | Dexa minims, atropine sulphate 1% minims | Prednisone 80 mg in a tapering regime |
| 9. 52/M | R | U | 14 | P | Query trachoma-induced | Removal of pseudopterygium | Dexa minims | Nil |
| 10. 72/F | L | B | 14 | T | Aniridia | CE/IOL, ectropion repair, EDTA | Bimatoprost 0.03%, minims pilocarpine nitrate 2%, refresh tears | Acetazolamide 125 mg BD |
| 11. 62/M | R | B | 15 | T | Multiple surgeries | PTK, PK (for corneal ectasia), CE/IOL | Dexa minims | Nil |
| 12. 81/M | L | U | 14 | T | Chemical burn | Nil | Atropine sulphate 1% minims, timolol/latanoprost, dexa minims | Nil |
| 13. 28/M | R | U | 9 | T | Chemical burn | BV diathermy | Dexa minims | Nil |
| 14. 65/F | L | B | 16 | T | CL over-wear | PK*, CE/IOL, PK + limbal tissue allograft* + tarsorrhaphy, DSEK | Predsol minims, latanoprost/timolol, atropine sulphate 1% minims | Nil |
| 15. 85/M | R | U | 14 | P | Limbal tumor excision; limbal surgeries | CE/IOL | Dexa minims, FML | Nil |
| 16. 80/F | R | B | 9 | T | Cicatrising conjunctivitis; ocular surface toxicity from glaucoma medication | CE/IOL, blepharoplasty | Dexa minims, cellufresh tears, timolol/latanoprost | Nil |
All patients were additionally prescribed minims chloramphenicol 0.5% post-operatively (not included in table). Asterisk (*) indicates previous surgical procedures to treat limbal stem cell deficiency (LSCD). Days in culture refers to the time to establish a reasonable number of cells on the contact lens before transplantation. BD, twice daily dosing; BV, blood vessel; CE/IOL, cataracts extraction/intraocular lens insertion; cellufresh tears, preservative free carboxymethylcellulose sodium 5 mg/mL; CL, contact lens; dexa minims, minims dexamethasone sodium phosphate 0.1%; DSEK, Descemet’s stripping endothelial keratoplasty; EDTA, ethylenediaminetetraacetic acid chelation therapy for band keratopathy; FML, flurometholone 1%; HAM, human amniotic membrane; PK, penetrating keratoplasty; predsol minims, minims prednisolone sodium phosphate 0.5%; PTK, phototherapuetic keratectomy;refresh tears, preservative free polyvinyl alcohol 1.4%; SK, superficial keratectomy.